Developing Topics.

Alzheimers Dement

Gerontological Society of America, Washington, DC, USA.

Published: December 2024

Adults with intellectual and developmental disabilities (I/DD) and their caregivers may face many barriers to obtaining an accurate assessment of cognitive decline. For example, primary care providers may mistake manifestations of new cognitive impairments or dementia for symptoms of the underlying disability. Pre-existing cognitive impairments, communication challenges, unfavorable reactions by members of the care team to adults with pre-existing cognitive deficits, and lack of understanding regarding common behaviors and needs of adults with I/DD can further complicate assessments. Furthermore, mainstream cognitive screening and assessment tools are not appropriate for many of the more than 7 million people living with I/DD in the United States. To address this unmet need and better equip primary care teams to appropriately address brain health in adults with I/DD, the Gerontological Society of America (GSA) developed a new companion resource to supplement The GSA KAER Toolkit for Brain Health. The four steps in the KAER framework-Kickstart, Assess, Evaluate, and Refer-are intended to improve health-related outcomes and well-being for people living with dementia and their families. The Toolkit includes practical approaches, educational resources, and validated clinical tools that help primary care teams implement initiatives related to brain health and timely detection of cognitive impairment. GSA developed the companion publication addressing the unique needs of adults with I/DD. The publication, Addressing Brain Health in Adults with Intellectual Disabilities and Developmental Disabilities: A Companion to the KAER Toolkit for Primary Care Providers, aims to: • Raise awareness of unique needs of adults living with I/DD. • Equip and encourage caregivers and health care teams to engage in appropriate brain health conversations with adults with I/DD. • Promote brain health conversations and early detection of changes in cognitive and adaptive function for adults with I/DD. • Assist with the identification of community supports and resource networks aimed at enhancing function and quality of life for adults with dementia and I/DD. This presentation will provide insights into the KAER framework and how, when combined with The GSA KAER Toolkit for Brain Health, the new companion can support person-centered brain health promotion, early detection of dementia, and dementia care planning for individuals with I/DD.

Download full-text PDF

Source
http://dx.doi.org/10.1002/alz.095609DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11713661PMC

Publication Analysis

Top Keywords

brain health
32
adults i/dd
20
primary care
16
care teams
12
kaer toolkit
12
i/dd •
12
adults
10
i/dd
10
health
9
adults intellectual
8

Similar Publications

Article Synopsis
  • A study evaluated the impacts of divalproex sodium on brain volumes in patients with mild to moderate Alzheimer’s disease using MRI scans over 24 months.
  • The results indicated that participants receiving divalproex experienced a significantly higher decline in hippocampal and brain volumes compared to those on placebo, along with a faster decline in cognitive function as measured by the Mini-Mental State Examination.
  • The findings suggest that divalproex treatment is linked to accelerated brain volume loss and potentially increased cognitive impairment, although the long-term effects remain unclear.
View Article and Find Full Text PDF
Article Synopsis
  • The study tested whether divalproex sodium (valproate) could prevent or delay agitation and psychosis in individuals with moderate Alzheimer's disease, enrolling 313 participants.
  • After two years of treatment, results showed no significant difference between the valproate and placebo groups regarding the time to development of agitation or psychosis.
  • Additionally, the valproate group experienced more side effects and showed greater reductions in brain volume, indicating potential adverse effects of the treatment.
View Article and Find Full Text PDF

Objective: To delineate the trajectories of Aβ42 level in cerebrospinal fluid (CSF), fludeoxyglucose F18 (FDG) uptake using positron emission tomography, and hippocampal volume using magnetic resonance imaging and their relative associations with cognitive change at different stages in aging and Alzheimer disease (AD).

Design: Cohort study.

Setting: The 59 study sites for the Alzheimer's Disease Neuroimaging Initiative.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!